Ischemic Stroke, Acute Clinical Trial
Official title:
Prospective International Multicenter Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety Evaluation of the Mexidol® Sequential Therapy of Patients in the Acute and Early Recovery Periods of Ischemic Stroke
Cerebral stroke is one of the most pressing clinical and social problems of modern medicine. According to WHO estimates, acute cerebral failure rank second among all causes of death. Optimizing the treatment of such conditions remains an urgent problem in neurology and rehabilitation.
Hypothesis: The addition of neurocytoprotectors to standard therapy in the acute and early recovery periods of Ischemic Stroke helps improve the results of further rehabilitation and reduce the severity of neurological deficit. The multimodal mechanism of action allows Mexidol® to realize a whole range of clinical effects, primarily such as anti-ischemic, vegetotropic, anti-amnestic, nootropic, anxiolytic, anticonvulsant, etc.). ;